+44 (0) 1223 737941 enquiries@cn-bio.com
  • Events
  • News
  • Facebook
  • Twitter
  • Linkedin
  • Youtube
  • Events
  • News
  • Facebook
  • Twitter
  • Linkedin
  • Youtube
CN Bio
  • Home
  • Organ-On-Chip
    • About Organ-On-Chip
    • Liver-On-a-Chip
    • Barrier Models
    • 3D Cell Culture
    • Toxicology
    • Drug Metabolism
    • Disease Modelling
  • Products
    • PhysioMimix™ OOC
    • Consumables
      • MPS-T12 plate
      • MPS-LC12 plate
      • MPS-TL6 plate
      • 3D validated cells
      • NASH-in-a-box
  • Services
    • NASH Fee-For-Service
    • Drug Metabolism and Safety Toxicity Testing Services
    • Oncology
  • Resources
    • Scientific Publications
    • Brochures
    • Videos
  • About us
    • The Company
    • Management Team
    • Careers
  • Contact
Select Page

CN Bio introduces PhysioMimix NASH ‘in-a-box’ reagent kit

by CN Bio. | Apr 26, 2022 | NASH, Press releases

First product within new ‘in-a-box’ range, which harnesses next-generation, human-relevant Liver-on-a-Chip technology to improve the accuracy and efficiency of NASH drug discovery Cambridge, UK, 26 April 2022: CN Bio, a leading Organ-on-a-chip Company (OOC) that...

NAFLD vs MAFLD: could a name change impact the progression of liver disease research?

by CN Bio. | Apr 21, 2021 | NASH

Liver disease is a serious worldwide problem linked to approximately two million deaths per year and in many cases is entirely preventable (Sumeet et al, 2019). One of the most common causes of chronic liver disease is non-alcoholic fatty liver disease (NAFLD), which...

How a novel in vitro Liver-on-a-Chip model of fatty liver disease is being used to help prevent a global healthcare crisis.

by CN Bio. | Jan 27, 2021 | NASH

Obesity is a global epidemic. Up to a third of the USA’s adult population is now obese and worldwide, the prevalence of obesity has almost tripled since the 1970s. Increased obesity has triggered a wave of serious associated health conditions, notably cardiovascular...

Recent Posts

  • CN Bio introduces PhysioMimix NASH ‘in-a-box’ reagent kit 26th April 2022
  • The lung in crisis: fighting back against pathogens, infections and inflammation with predictive in vitro respiratory models that accelerate drug discovery 23rd March 2022
  • Debunking the 9 Myths of Organ-on-a-Chip Technology 24th February 2022

Categories

  • Blog
  • Business
  • Media Coverage
  • NASH
  • OOC Blog
  • Press releases
  • Uncategorised
Website built and designed by Website Energizers LTD | © 2021 CN Bio Innovations | Registered No. 06517359 | VAT No. 978184563
Privacy Policy | Terms | Sitemap | Regulatory